|
4d Molecular Therapeutics Inc (NASDAQ: FDMT) |
|
|
|
|
Select the Financial Report:
|
|
Select the Period:
|
|
Description of 4d Molecular Therapeutics Inc's Business Segments
4D Molecular Therapeutics Inc (4DMT) is a pioneering company in the gene therapy sector, recognized for its innovative and targeted approach to developing vector-based gene therapies. Here's an extensive overview of the segments, products, and services that define 4DMT's operational landscape:
Segments
1. Research and Development (R&D):
- Vector Discovery Platform (VDP): At the core of 4DMT's R&D efforts is its proprietary VDP, which plays a crucial role in identifying novel gene therapy targets. The platform employs advanced computational and experimental techniques to discover vectors tailored to specific therapeutic needs.
- Disease Biology Understanding: The R&D segment collaborates with researchers to deepen insights into the biological mechanisms of various diseases, facilitating the identification of ideal targets for gene therapy interventions.
2. Vector Development and Production:
- Viral Vector Creation: This segment is dedicated to the engineering of viral vectors, particularly adeno-associated viral (AAV) vectors, known for their safety and efficacy in gene delivery. 4DMT focuses on creating vectors that optimize the delivery of therapeutic genes to designated cells, enhancing treatment effectiveness.
- Scalability and Quality Control: 4DMT emphasizes robust processes that support the scalable production of vectors while maintaining rigorous quality control standards to meet both preclinical and clinical study requirements.
Products
1. Targeted Vector Library:
- 4DMT has established a comprehensive Targeted Vector Library, which comprises a wide array of AAV vectors engineered for specificity in targeting different tissues and cell types. This library serves as a fundamental resource for developing tailored gene therapies aimed at addressing a variety of genetic disorders.
2. Gene Therapy Candidates:
- Pipeline of Therapies: The company's pipeline features several advanced gene therapy candidates, notably targeting ocular diseases (like retinal dystrophies), cardiovascular conditions (such as heart failure due to genetic mutations), and neurological disorders (including various types of muscular dystrophies). Each candidate is designed to deliver therapeutic genes that can potentially rectify underlying genetic anomalies.
- Innovation in Therapeutic Delivery: By leveraging optimized vector technology, these gene therapies aim to achieve high levels of gene expression in target tissues, providing robust therapeutic effects with minimized off-target effects.
Services
1. Vector Design and Optimization:
- Through its specialized services, 4DMT provides organizations with expert guidance in vector design and performance optimization. This involves customizing vectors to improve specificity for target cell types, enhancing delivery efficiency, and ensuring successful integration of therapeutic genes.
2. Collaboration and Licensing:
- 4DMT actively seeks partnerships with academic research institutions, biotechnology firms, and pharmaceutical companies to co-develop gene therapies. This includes licensing agreements that grant partners access to their Targeted Vector Library and expertise in vector design, allowing for collaborative advancements in gene therapy research.
3. Vector Manufacturing:
- The company operates a state-of-the-art manufacturing facility capable of producing high-quality AAV vectors at scale for both preclinical and clinical applications. This infrastructure supports the robust supply chains necessary for research and development activities as well as clinical trial executions.
- Custom Manufacturing Solutions: 4DMT can accommodate various production scales, responding flexibly to the needs of its partners and projects.
4. Regulatory Support:
- Navigating the intricacies of regulatory environments is critical in gene therapy development. 4DMT provides extensive regulatory support, including preparation for regulatory submissions and advice on how best to meet industry standards and requirements. This ensures that partners can effectively transition their therapies from preclinical stages through to clinical trials while maintaining compliance.
Conclusion
4D Molecular Therapeutics Inc stands at the forefront of gene therapy innovation, effectively leveraging its Vector Discovery Platform, Targeted Vector Library, and comprehensive services to revolutionize the treatment of a wide array of diseases. Through its focus on R&D, vector development, and strong partnerships, 4DMT aims to make significant contributions to the gene therapy landscape, offering novel solutions to patients with unmet medical needs.
Composition of 4d Molecular Therapeutics Inc Revenues by
Segments |
| |
| Cystic Fibrosis Foundation |
|
 100 % |
of total Revenue |
Q1 three months ended (Mar 31 2025)
|
| Revenues by Business Segments |
Revenues
(in millions $) |
%
(of total Revenues) |
| Cystic Fibrosis Foundation |
0.01 |
100 % |
| Total |
0.01 |
100 % |
Q1 three months ended (Mar 31 2025)
|
| Revenue Growth rates by Segment |
Y/Y Revenue
% |
Q/Q Revenue
% |
| Cystic Fibrosis Foundation |
-50 % |
- |
| Total |
-50 % |
-62.16 % |
Q1 three months ended (Mar 31 2025)
|
| Income by Business Segments |
Income
(in millions $) |
%
(Profit Margin) |
| Total |
-47.97 |
- |
Q1 three months ended (Mar 31 2025)
|
| Income Growth rates by Segment |
Y/Y Income
% |
Q/Q Income
% |
| Total |
- |
- |
Annual Report on 4d Molecular Therapeutics Inc Divisions, Sales by Country |
| |
| United States |
|
100 % |
of total Revenue |
| Collaboration and License Revenue |
|
100 % |
of total Revenue |
| Collaboration and License Revenue CFF |
|
100 % |
of total Revenue |
Twelve months ended 2024
|
| FDMT s Annual Revenue by Geography and Business Segments |
Sales
(in millions $) |
%
(of total Sales) |
| Total |
0.04 |
100 % |
| United States |
0.04 |
100 % |
| Collaboration and License Revenue |
0.04 |
100 % |
| Collaboration and License Revenue CFF |
0.04 |
100 % |
Twelve months ended 2024
|
| FDMT s Annual Income by Country and Business Segments |
Income
(in millions $) |
%
(Profit Margin) |
| Total |
-160.87 |
- |
Twelve months ended 2024
|
| Annual Revenue and Income Growth by Country and Business Segments |
% Y/Y Sales Growth |
% Y/Y Income Growth |
| Total |
-99.82 % |
- |
| United States |
-99.82 % |
- |
| Collaboration and License Revenue |
-99.82 % |
- |
| Collaboration and License Revenue CFF |
-75 % |
- |
| Netherlands |
- |
- |
| Collaboration and License Revenue uniQure |
- |
- |
| Collaboration and License Revenue Astellas |
- |
- |
|
|
